



## BSW Formulary Updates and Recent Decisions – April 2024

### New additions to BSWformulary and Change in Traffic Light Status

- [Nutrizym 22 oral pancreatin capsules](#) – added as **amber**. Included as a second line option to support ongoing stock shortages in pancreatic enzyme replacement therapies.
- [Filgrastim 12million units/0.2ml solution for injection PFS](#) – added as **red**.
- [Furosemide 50mg/5ml ampoules](#) – changed from **red** to **amber** TLS when prescribed on the advice of a specialist palliative care team for (off-label) subcutaneous use in syringe driver for the treatment of heart failure in palliative care.
- [Propylthiouracil tablets](#) – aligned as **amber**.
- [Freestyle Libre 2 Plus](#) (FSL2+) added as **amber**. This product will replace Freestyle Libre 2. Note that FSL2+ sensors are worn for 15 days vs 14 days for FSL2 sensors. Read more here: [How is FreeStyle Libre 2 Plus sensor different from FreeStyle Libre 2 sensor? – FAQ](#)
- [Dexcom One Plus](#) added as **amber**. This product will replace Dexcom One.

### New and Updated Shared Care Agreements and Prescribing Guidance

- **UPDATE – [BSW SCA for subcutaneous methotrexate for patients in adult services \(excluding cancer care\)](#)**. This BSW document covers all three acute Trusts in BSW and replaces previous, separate locality versions of the subcut methotrexate SCA.
- **UPDATE - [BSW Summary of Shared Care Guidelines And Monitoring of Disease Modifying Drugs \(DMARDs\) in ADULTS](#)**. Minor typographical amendment to include the correct link to the newly aligned BSW SCA for subcut methotrexate.

### Minor amendments to Netformulary

- [Sitagliptin](#) now has the lowest acquisition cost and becomes first line DPP-4 for new patients. When reviewing patients on alternative DPP-4s consider switching to sitagliptin where clinically indicated. If there is no beneficial improvement in HBA1c, review treatment options in line with [NICE NG28](#). Stop DPP-4 inhibitor (gliptin) if starting a GLP-1; both classes of drug work on the same pathway so no additional HBA1c benefit is achieved using both together.

### What the BSW CCG formulary team are currently working on

- Aligning TLS and SCAs for alfacalcidol use across BSW.
- An application to incorporate the use of cytosine 1.5mg tablets into an updated local smoking cessation guide.
- Working with our commissioners to review tier 3 obesity services in order to provide the semaglutide option in line with NICE TA875.
- Working as a collaborative Integrated Care System diabetes group to implement Hybrid Closed Loop system provision in line with NICE TA943.
- Supporting the primary care team with a BSW LES review.
- Reviewing the current BSW Sativex policy



Bath and North East Somerset,  
Swindon and Wiltshire Together

*The BSW joint formulary remains under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems and Optimise Profiles are in line with the joint formulary. If you discover information you believe to be inaccurate or misleading, or for further information, email [bswib.formulary@nhs.net](mailto:bswib.formulary@nhs.net)*